Resverlogix Corp. Announces Agreement with Leading Pharmaceutical Research Organization

CALGARY, AB, Nov.10, 2004 – Resverlogix Corp. ("Resverlogix") (TSX-V: RVX), is pleased to announce its pre-clinical research agreement with NAEJA Pharmaceutical Inc., a leader in pre-clinical drug development. NAEJA is a well recognized pharmaceutical contract research and development company with extensive expertise in the areas of cardiovascular, cancer, central nervous system and infectious disease.

"This agreement with a pre-eminent research organization like NAEJA will help expedite and further validate our cardiovascular NEXVAS? clinical program. NAEJA will provide important validation of our primary lead compounds" stated Dr. Jan Johansson, Senior Vice President of Clinical Affairs at Resverlogix. "In addition NAEJA will further provide important biopharmaceutical profiling for our backup compounds as well. With this additional caliber of pre-clinical expertise behind Resverlogix's development program, we gain the significant ability to move our NEXVAS? technology forward" noted Dr. Johansson.

About NAEJA Pharmaceutical Inc.

NAEJA specializes in pre-clinical drug discovery and contract research up to the IND stage for the innovative pharmaceutical industry. The company has 50,000 ft² of world class laboratory facilities with corporate offices in both Edmonton and San Diego. NAEJA employs over 100 leading scientific researchers, 80 of which hold Ph.D's with expertise in all aspects of drug development including, lead optimization, biopharmaceutical profiling, microbiology and custom synthesis. The company has an impressive international life-sciences research clientele combined with a successful record of internally developed products that currently are marketed through global innovative pharmaceutical organizations. NAEJA is a privately held company. For further information, please visit their web site at: www.naeja.com.

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NEXVAS™, applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The Company's second technology TGF-Beta Shield? utilizes an adoptive immunotherapy approach to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Venture Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Donald J. McCaffrey
President/CEO
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: don@resverlogix.com
Website: www.resverlogix.com

Ronald G. Micetich, Ph.D.
President and CEO
NAEJA Pharmaceutical Inc.
Phone: 780-462-4044
Email: info@naeja.com
Website: www.naeja.com